ArticleResearch square2025
Airway Delivery of Encapsulated Cytokine-Secreting Cells for Local Immunomodulation in Inflammatory Lung Diseases.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Dysregulated lung immunity drives excessive inflammation, leading to diseases like acute respiratory distress syndrome (ARDS) and pulmonary fibrosis that have high morbidity and mortality. Immunomodulation can attenuate inflammation and improve outcomes, however off-target effects from systemic delivery lead to adverse events that limit clinical translation. Herein, we develop a modular cell-based microcapsule platform that can be administered via the airway for localized, durable, and tunable delivery of various immunomodulatory proteins to the lungs. With this system, we demonstrate therapeutic efficacy of localized delivery of two proteins, interleukin-10 (IL-10) and interleukin-1 receptor antagonist (IL-1Ra), in a lipopolysaccharide-induced rodent model of ARDS. Single-cell RNA sequencing revealed that IL-10-secreting capsules reprogram the lung immune landscape in ARDS by altering myeloid cell composition, suppressing pro-inflammatory gene expression, and promoting the resolution of inflammation. In a bleomycin pulmonary fibrosis model, the platform enables durable and sustained delivery of IL-10 to alleviate hypoxemia and rescue lung architecture. Safety and biocompatibility were further confirmed in a large animal model, highlighting the clinical potential of the platform for the treatment of inflammatory lung diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.